NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, Price Target & More

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) posted its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.15. The biotechnology company had revenue of $4.15 million for the quarter, compared to analyst estimates of $11.39 million. Pieris Pharmaceuticals had a negative return on equity of 96.56% and a negative net margin of 65.40%. View Pieris Pharmaceuticals' Earnings History.

5 brokers have issued twelve-month price targets for Pieris Pharmaceuticals' stock. Their predictions range from $12.00 to $13.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $12.3333 in the next twelve months. View Analyst Ratings for Pieris Pharmaceuticals.

Some companies that are related to Pieris Pharmaceuticals include Sorrento Therapeutics (SRNE), National Research (NRCIA), Eloxx Pharmaceuticals (ELOX), Viralytics (VRACY), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), BIOQUAL (BIOQ), Vitality Biopharma (VBIO), Cleveland BioLabs (CBLI), Protalex (PRTX), Bioanalytical Systems (BASI) and US Stem Cell (USRM).

Media headlines about PIRS stock have been trending positive this week, Accern reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a media sentiment score of 0.26 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 47.13 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Pieris Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (6.67%), Millennium Management LLC (3.38%), BlackRock Inc. (3.34%), Omega Fund Management LLC (1.45%), Prosight Management LP (1.05%) and Northern Trust Corp (0.66%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.

PIRS stock was sold by a variety of institutional investors in the last quarter, including Omega Fund Management LLC. View Insider Buying and Selling for Pieris Pharmaceuticals.

PIRS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, BVF Inc. IL, Prosight Management LP, BlackRock Inc., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Wedge Capital Management L L P NC and EAM Global Investors LLC. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PIRS stock can currently be purchased for approximately $5.15.

Pieris Pharmaceuticals has a market capitalization of $279.13 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]